NEW YORK (GenomeWeb) – Interpace Diagnostics reported yesterday a 32 percent rise in third quarter revenues, in part due to an increase in test and collection volume for its thyroid cancer diagnostics.

For the three-month period ended Sept. 30, Interpace's revenues climbed to $3.3 million from $2.5 million the year before, due in part to higher test and collection volume for the company's ThyraMir and ThyraGenX thyroid cancer assays. Also driving revenues was an increase in the amounts collected based on Medicare coverage for ThyraMir.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.